Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Björkholm M, Dickman PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168(5):317–325.
   PubMed Web of Science ®Google Scholar
• Rungjirajittranon T, Owattanapanich W, Ungprasert P, et al. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019;19(1):184.
   PubMedGoogle Scholar
• Hultcrantz M, Wilkes SR, Kristinsson SY, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in sweden between 1973 and 2005: a population-based study. J Clin Oncol. 2015;33(20):2288–2295.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Ruggeri M, Cervantes F, et al. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia. 2016;30(10):2032–2038.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599–1613.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Vannucchi AM, Griesshammer M, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European leukemianet 2021 recommendations. Lancet Haematol. 2022;9(4):e301–e11.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Finazzi G, Barbui T. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. Blood Cancer J. 2018;8(7):65.
   PubMedGoogle Scholar
• Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–e81.
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2017;378(7):615–624.
   PubMed Web of Science ®Google Scholar
• Curto-Garcia N, Doyle AJ, Breen KA, et al. Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK. Br J Haematol. 2020;189(3):e79–e81.
   PubMed Web of Science ®Google Scholar
• McBane RD 2nd, Wysokinski WE, Le‐Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–421.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
   PubMed Web of Science ®Google Scholar
• Ianotto J-C, Couturier M-A, Galinat H, et al. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol. 2017;106(4):517–521.
   PubMed Web of Science ®Google Scholar
• Barbui T, De Stefano V, Carobbio A, et al. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia. 2021;35(10):2989–2993.
   PubMed Web of Science ®Google Scholar
• Serrao A, Breccia M, Napolitano M, et al. A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with Ph-negative myeloproliferative neoplasms. Am J Hematol. 2020;95(12):E329–E32.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694.
   PubMed Web of Science ®Google Scholar
• Kaatz S, Ahmad D, Spyropoulos AC, et al. Anticoagulation tSoCo. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–2126.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
   PubMed Web of Science ®Google Scholar
• Huenerbein K, Sadjadian P, Becker T, et al. Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms. Ann Hematol. 2021;100(8):2015–2022.
   PubMed Web of Science ®Google Scholar
• Fedorov K, Goel S, Kushnir M, et al. Thrombosis in myeloproliferative neoplasms: treatment outcomes of direct oral anticoagulants and vitamin K antagonists. Res Pract Thromb Haemost. 2021;5(6):e12574.
   PubMed Web of Science ®Google Scholar
• How J, Story C, Ren S, et al. Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. Blood Cancer J. 2021;11(11):176.
   PubMed Web of Science ®Google Scholar
• Herbreteau L, Papageorgiou L, Le Clech L, et al. Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms. Thromb Res. 2022;216:25–34.
   PubMed Web of Science ®Google Scholar
• Raso S, Santoro M, Napolitano M, et al. PB2441 direct oral anticoagulation in patients with myeloproliferative neoplasms: a single-center real-life experiencE. HemaSphere. 2019;3(S1):1081.
   Google Scholar
• Deloughery EP, McBane RD, Ashrani AA, et al. Direct oral anticoagulants in patients with myeloproliferative neoplasms: a single institution retrospective study. Blood. 2018;132(Supplement 1):5067.
   Google Scholar
• Schoenbeck KL, Salmasi G, Cerejo MC, et al. Direct oral anticoagulant use and outcomes in patients with high and intermediate risk BCR-ABL-negative myeloproliferative neoplasms. Blood. 2019;134(Supplement_1):1165.
   Google Scholar
• Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(3):348–358.
   PubMed Web of Science ®Google Scholar
• Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914–918.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res. 2015;135(Suppl 1):S8–s11.
   PubMed Web of Science ®Google Scholar
• Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153.
   PubMed Web of Science ®Google Scholar
• Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active Cancer: a randomized clinical trial. JAMA. 2015;314(7):677–686.
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with Cancer with venous thromboembolism: results of a randomized trial (SELECT-D). Am J Clin Oncol. 2018;36(20):2017–2023.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with Cancer. N Engl J Med. 2020;382(17):1599–1607.
   PubMed Web of Science ®Google Scholar
• Schrag D, Uno H, Rosovsky RPG, et al. The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: the CANVAS pragmatic randomized trial. J Clin Oncol. 2021;39(15_suppl):12020.
   Web of Science ®Google Scholar
• Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3):781–790.
   PubMed Web of Science ®Google Scholar
• Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–e47.
   PubMed Web of Science ®Google Scholar
• Sozer S, Fiel MI, Schiano T, et al. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246–5249.
   PubMed Web of Science ®Google Scholar
• Rosti V, Villani L, Riboni R, et al. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood. 2013;121(2):360–368.
   PubMed Web of Science ®Google Scholar
• Hekimoglu H, Toprak SF, Sozer S. JAK2V617F-positive endothelial cells induce apoptosis and release jak2v617f-positive microparticles. Turk J Haematol. 2022;39(1):13–21.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372–380.
   PubMed Web of Science ®Google Scholar
• Hernández-Boluda J-C, Arellano-Rodrigo E, Cervantes F, et al. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol. 2015;94(6):911–918.
   PubMed Web of Science ®Google Scholar
• Naymagon L, Tremblay D, Zubizarreta N, et al. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv. 2020 Feb 25;4(4):655–666.
   PubMed Web of Science ®Google Scholar
• Janczak DT, Mimier MK, McBane RD, et al. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location. Mayo Clin Proc. 2018 Jan;93(1):40–47.
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, De Stefano V. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost. 2022;6(1):e12657.
   PubMed Web of Science ®Google Scholar
• Jones E, Dillon B, Swan D, et al. Practical management of the haemorrhagic complications of myeloproliferative neoplasms. Br J Haematol. 2022;199(3):313–321.
   PubMed Web of Science ®Google Scholar